image1 (1).png
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
09 sept. 2024 07h00 HE | Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Intravacc logo.png
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
16 janv. 2024 06h00 HE | Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Transparency Market Research
Gonorrhea Therapeutics Market Surpass USD 2 billion in Revenues by 2027 Says, Transparency Market Research
26 sept. 2023 10h30 HE | Transparency Market Research
Wilmington, Delaware, United States, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - According to TMR, gonorrhea therapeutics are expected to expand at a 5.3% CAGR from 2019...
Logo.png
Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape 
24 mars 2021 21h10 HE | DelveInsight Business Research LLP
Los Angeles, USA, March 24, 2021 (GLOBE NEWSWIRE) -- Gonorrhea Pipeline Analysis: Emerging Therapies and Key Companies Transforming the Gonorrhea Landscape  Gonorrhea Pipeline report provides...
ezgif.com-gif-maker.png
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
30 sept. 2019 01h00 HE | Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Summit Master_rgb_png.png
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
17 juil. 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...
Summit Master_rgb_png.png
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
20 juin 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...
Summit Master_rgb_png.png
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
14 mars 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
Summit Master_rgb_png.png
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
25 févr. 2019 07h00 HE | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
SpeeDx-SMALL--Master.png
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
06 déc. 2018 03h30 HE | SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...